This study investigated the outcomes of patients with rectal cancer who were followed up with the watch and wait method after chemoradiotherapy (CRT). Researchers suggested that this strategy can effectively identify patients who can have a less frequent follow-up if they maintain response for the first 3 years after treatment.

This study evaluated the benefit of adding hyperthermic intraperitoneal chemotherapy (HIPEC) to cytoreductive surgery (CS) for the treatment of colorectal cancer (CRC) that has spread to the peritoneum (the lining of the abdomen that covers all abdominal organs). The study found that HIPEC added to CS did not improve the outcomes of these patients.

This study compared the effectiveness of electron beam radiotherapy (EBR) and high-dose brachytherapy (HDB) during surgery in patients with rectal cancer who underwent an incomplete removal of the cancer. Researchers suggested that HDB was associated with a lower risk of recurrence in these patients. 

This study evaluated whether surgery of colorectal cancer (CRC) followed by chemotherapy (CT) improved the outcomes of patients with metastatic (spread) CRC compared to CT alone. The study found that there was no difference in patients' outcomes whether surgery was given or not.

This study investigated the effectiveness and safety of computed tomography (CT)-guided radioactive ¹²⁵Iodine (RI) implantation in patients with recurrent locally advanced rectal cancer (LARC). Researchers suggested that CT-guided RI implantation is a good and safe treatment for patients with LARC that came back after previous treatment.

This study investigated if reducing therapy duration could reduce side effects in patients but still be effective in patients with stage II colorectal cancer (CRC). This study showed that in certain patients a 3-month treatment duration can be considered. 

This study evaluated the timing between chemoradiotherapy (CRT) and surgery in patients with locally advanced rectal cancer (LARC). The study found that patients who had surgery more than 10 weeks after CRT had the best outcome.

This study investigated the effectiveness and safety of stereotactic ablative radiation therapy (SABR) in the treatment of patients with oligometastatic (few metastases) cancer. The data showed that the use of SABR in these patients was associated with high overall survival and low toxicity.

This study evaluated reasons for a delay to ileostomy closure in patients who underwent anterior resection for rectal cancer. This study showed that factors such as having chemotherapy or cancer progression may delay ileostomy closure.

This study compared the use of chemotherapy and bevacizumab (Avastin) or panitumumab (Vectibix) for the treatment of left-sided metastatic colorectal cancer (mCRC) without BRAF/RAS mutations (permanent changes in genes). The study found that both treatment options are effective for these patients.